Progress Report from RVX-208 Phase 1 Clinical Study
CALGARY, January 14, 2008 /PRNewswire-FirstCall/ - Resverlogix is pleased to announce preliminary data from the RVX-208 Phase 1 safety and pharmacokinetics study. Forty healthy volunteers have so far been treated of which sixteen have received multiple doses. As anticipated from the extensive Investigational New Drug toxicology studies no safety and tolerance problems have been encountered at any of the given doses. "The pharmacokinetics (drugability) of RVX-208 has exceeded our highest expectations," stated Donald J. McCaffrey, President & CEO of Resverlogix. "We are very confident about the further progress of the RVX-208 clinical program and the eventual successful completion of Phase 1. The current phase 1 study includes a total of 80 healthy men and women in a study comprising three arms: single dose escalation, food vs. fasted effect on pharmacokinetics and 3 cohorts with 7-day multiple dosing."
McCaffrey noted, "Due to the successful early trending of our Phase 1 program we have decided that upon official completion of the trial, FDA discussions and approval, we will be expediting our plans for a Phase 2 trial. This could shorten the time to reach our Phase 2 trial by several months. In addition, follow on studies in cardiovascular disease patients are being discussed with potential collaborators. The medical community recognizes that permanently increasing ApoA-I production, plasma HDL and promoting reverse cholesterol transport by a small molecule has unprecedented potential to cure atherosclerosis."
About Cardiovascular Disease (CVD)
CVD can be generally defined as any abnormal condition characterized by dysfunction of the heart and blood vessels. CVD includes atherosclerosis (especially coronary heart disease which can lead to heart attacks), cerebrovascular disease (stroke), and hypertension (high blood pressure). The underlying cause of most CVD is a gradual clogging of the arteries (atherosclerosis) that supply blood to the heart, brain and other vital organs.
The American Heart Association estimates that almost 80 million American Adults have one or more types of cardiovascular disease. CVD remains the number one killer of developed nations. Nearly 2400 Americans die each day from cardiovascular disease - that is 1 person will die every 36 seconds.
About Resverlogix Corp.
Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet needs. The NexVas(TM) program is the Company's primary focus which is to develop novel small molecules that enhance ApoA-I. These vital therapies address the grievous burden of atherosclerosis and other important diseases such as acute coronary syndrome, diabetes, Alzheimer's and other vascular disorders. The Company's secondary focus is TGF-Beta Shield(TM), a program that aims to address burgeoning grievous diseases, such as cancer and fibrosis. Resverlogix Corp. trades on the Toronto Stock Exchange . For further information please visit www.resverlogix.com.
This news release may contain certain forward-looking statements that reflect the current views and/or expectations of Resverlogix Corp. with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly. The TSX Exchange does not accept responsibility for the adequacy or accuracy of this news release.
CONTACT: Theresa Kennedy, VP, Corporate Communications, Resverlogix Corp.,Phone: (604) 538-7072, Fax: (403) 256-8495, Email: ;Sarah Zapotichny, Manager, Investor Relations, Resverlogix Corp., Phone:(403) 254-9252, Fax: (403) 256-8495, Email: ; Website:www.resverlogix.com Theresa@resverlogix.com Sarah@resverlogix.com
Ticker Symbol: (Toronto:RVX.)
Terms and conditions of use apply
Copyright © 2008 PR Newswire Association LLC. All rights reserved.
A United Business Media Company
Posted: January 2008